![]() |
|
|
Vol. 27, Issue 1, 46-52, January 1999
Department of Comparative Biosciences and Environmental Toxicology
Center,
| |
Abstract |
|---|
|
|
|---|
Flavin-containing monooxygenase (FMO) 3 is the predominant FMO isoform in adult human liver; however, little is known about its expression in common laboratory species. Studies have shown FMO3 levels to be sex-dependent in mouse liver, but not in human liver. The current study was undertaken to determine the expression of FMO3 in liver and kidney microsomes from multiple species, and to determine whether the sex dependence seen in mouse liver extends to other species and/or tissues. FMO3 had previously been shown to be the major FMO involved in methionine S-oxidation in rat and rabbit liver microsomes. In this study, species differences in FMO3 levels were assessed in liver microsomes from humans, rats, dogs, mice, and rabbits, and in kidney microsomes from rats, dogs, mice, and rabbits, by comparing methionine S-oxidase activities. Species differences were noted in male liver microsomes, with rabbits having 3-fold higher methionine S-oxidase activity than mice and dogs and 1.5-fold higher activity than humans and rats. Species differences were also noted in male and female kidney microsomes, with rats exhibiting 2- to 6-fold higher methionine S-oxidase activity than the other species. Sex differences in FMO3 levels were assessed using methionine S-oxidase activity and immunoblotting, and were noted only in liver microsomes from mice and dogs, with females having higher levels than males. Results also show that FMO3 orthologs from multiple species are catalytically similar with regard to methionine, S-allyl-L-cysteine, and S-(1,2-dichlorovinyl)-L-cysteine S-oxidations.
| |
Introduction |
|---|
|
|
|---|
Flavin-containing monooxygenases
(FMOs)1 are
microsomal enzymes that catalyze the NADPH- and
O2-dependent oxidation of many nitrogen-,
sulfur-, selenium-, and phosphorus-containing compounds (Ziegler,
1993
). Five isoforms of FMO have been identified thus far (FMO1-FMO5),
each exhibiting its own unique species- and tissue-dependent expression
(Hines et al., 1994
). The predominant FMO isoform in adult
human liver is FMO3. This isoform catalyzes oxidation of several
important drugs and xenobiotics such as methimazole, chlorpromazine, and nicotine (Cashman et al., 1995
; Overby et al., 1997
), as
well as the oxidation of alkenyl cysteine conjugates (Ripp et al., 1997a
). FMO3 has also been shown to be the major enzyme responsible for
methionine S-oxidation in rat and rabbit liver microsomes (Duescher et al., 1994
; Krause et al., 1996
). Although methionine can
also be oxidized by FMO1 and FMO2, the Km
values for these reactions are much higher (50 mM and 30 mM,
respectively) than the Km value for
oxidation by FMO3 (approximately 5 mM). Recently, FMO3 has been
identified as the enzyme responsible for N-oxidation of
trimethylamine, and mutations in this isoform result in the human
disease trimethylaminuria (Dolphin et al., 1997
). Oxidation of a
chemical by FMO3 can result in the formation of a metabolite that is
more readily excreted than the parent chemical, as is the case for
trimethylamine. FMO3-mediated oxidations can also result in increased
toxicity, as is the case for
S-(1,2-dichlorovinyl)-L-cysteine (DCVC) (Sausen
and Elfarra, 1991
; Lash et al., 1994
; Ripp et al., 1997a
). Thus,
whether oxidation by FMO3 is a detoxication or a bioactivation reaction
depends on the chemical being oxidized.
Despite the fact that FMO3 is an important enzyme for drug metabolism
and is the predominant FMO isoform in human liver, little is known
about its distribution in other species and tissues. FMO3 messenger RNA
(mRNA) levels have been qualitatively assessed in liver from rats,
rabbits, mice, hamsters, and guinea pigs (Burnett et al., 1994
).
However, mRNA levels have been shown to not correlate well with actual
protein levels of FMO3 (Overby et al., 1997
). Therefore, species
differences in hepatic expression of FMO3 protein remain to be
investigated. Information about the distribution of FMO3 in laboratory
animals is important because these animals are used in research to
model human metabolism and toxicity.
FMO3 expression has been shown to be sex-dependent in mouse liver in
that females express this isoform and males do not (Falls et al.,
1995
). This sex-dependence appears to be due to repression of FMO3
expression by testosterone (Falls et al., 1997a
). The expression of
FMO3 does not appear to show sex-dependence in human liver (Cashman et
al., 1993
; Sadeque et al., 1993
). It is not known, however, whether or
not other laboratory species, such as rats, rabbits, or dogs, exhibit
sex differences in FMO3 expression, or if this is a mouse-specific phenomenon.
There has been very little characterization of FMO3 levels in the
kidney. FMO3 mRNA levels have been qualitatively assessed in the
kidneys of rats, rabbits, mice, hamsters, and guinea pigs (Burnett et
al., 1994
), but again, mRNA levels are not a good indicator of actual
protein levels for FMO3. FMO3 mRNA levels have been quantitatively
assessed in the adult human kidney and were detectable, but present in
much lower levels than in the adult human liver (Dolphin et al., 1996
).
FMO3 was not detectable by Western or Northern blot analysis in the
male or female mouse kidney (Falls et al., 1997b
). However, FMO3 levels
in kidneys from other important laboratory species remain to be investigated.
One goal of this study was to systematically assess levels of FMO3
protein in liver microsomes from several common laboratory species,
both males and females, and compare them to human FMO3 levels. Another
goal was to examine species and sex differences in FMO3 in kidney
microsomes from these species. Because much of what was previously
known about hepatic and renal FMO3 distribution was based on mRNA
levels, another goal of this study was to use an activity assay to
assess FMO3 protein levels among species. FMO3 levels were then
determined using both this activity assay and immunoblotting
techniques. Preliminary results from these studies have been reported
(Ripp et al., 1997b
, 1998
).
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals.
DCVC, DCVC sulfoxide, and
S-allyl-L-cysteine (SAC) sulfoxide were
synthesized as previously described (Ripp et al., 1997a
). SAC was a
gift from Wakunaga Pharmaceutical of America (Mission Viejo, CA).
L-Methionine,
L-methionine-dl-sulfoxide, flavin adenine dinucleotide, flavin mononucleotide, and NADPH were obtained from Sigma
(St. Louis, MO). 2,4-Dinitro-1-fluorobenzene and trifluoroacetic acid were obtained from Aldrich (Milwaukee, WI). High-pressure liquid
chromatography (HPLC)-grade acetonitrile was purchased from EM
Science (Gibbstown, NJ).
Biological Materials.
Escherichia coli membrane fractions containing complementary
DNA (cDNA)-expressed rabbit FMO3 or human FMO3 were obtained as
previously described (Burnett et al., 1994
; Itagaki et al., 1996
).
Flavin contents were determined by HPLC with fluorescence detection as
previously described (Ripp et al., 1997a
). Human liver samples were
purchased from SRI International (Menlo Park, CA). All human livers
were from adult Caucasians ranging in age from 22 to 45 years old. New
Zealand White rabbit (8-12 weeks old) livers and kidneys were obtained
from Pel-Freez Biologicals (Rogers, AR). Sprague-Dawley rats (8-10
weeks old) were purchased from Sasco (Omaha, NE) and B6C3F1 mice (6-8
weeks old) were purchased from The Jackson Laboratory (Bar Harbor, ME).
Adult dog (hound-cross) livers and kidneys were obtained from control
animals in experiments carried out at the School of Veterinary Medicine
(Madison, WI). Microsomes were prepared by differential centrifugation
as previously described (Sausen and Elfarra, 1990
). Protein
concentrations were determined by the method of Lowry et al. (1951)
using bovine serum albumin as a standard.
Enzyme Assays.
The buffer used in all experiments was 0.1 M KCl, 0.1 M
KH2PO4, 5 mM EDTA, pH 7.4. Microsomes (0.2-0.7 mg liver; 0.1-0.3 mg kidney) or E. coli membrane fractions (0.4-0.9 nmol flavin) were preincubated
at 37°C for 5 min in the presence of NADPH (2 mM final) in a shaking
water bath and reactions were started by the addition of substrate.
Final reaction volume was 0.5 ml. Control reactions lacking NADPH or
with zero incubation time were run in parallel to correct for any
nonenzymatic sulfoxidation. Reactions were stopped with either 0.5 ml
of ice-cold ethanol (methionine and SAC) or 0.5 ml of ice-cold 0.75%
perchloric acid (DCVC). Reactions were then vortexed and
centrifuged for 15 min at 3000 rpm to removed precipitated proteins.
Supernatants from DCVC reactions were filtered and analyzed directly by
HPLC with UV detection at 220 nm as previously described (Ripp et al.,
1997a
). Supernatants (0.7 ml) from SAC and methionine reactions were
derivatized with 18 µl of 2,4-dinitro-1-fluorobenzene (10%
v/v in ethanol). Derivatization of SAC reactions was complete after
heating at 60°C for 1 h. Derivatization of methionine reactions was complete after heating at 37°C for 30 min and then allowing the
reaction to proceed at room temperature for at least 6 h. Derivatized reaction mixtures were stable for at least 24 h and were analyzed by HPLC with UV detection at 360 nm as previously described (Duescher et al., 1994
; Ripp et al., 1997a
).
Immunoblotting.
All experiments contained, as standards, one lane of prestained
molecular weight markers (Bio-Rad, Hercules, CA) and one lane of
E. coli membrane fractions containing cDNA-expressed rabbit FMO3. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (12% resolving gel), followed by transfer to
polyvinylidene difluoride membranes. Membranes were blocked with 5%
normal donkey serum (Jackson ImmunoResearch, West Grove, PA) in
Tris-buffered saline with 0.1% Tween 20. Goat anti-rabbit FMO3 primary
antibody (monospecific for FMO3, as described in Overby et al., 1997
)
was used at a 1:1000 dilution. Secondary antibody (donkey anti-goat IgG
conjugated to alkaline phosphatase; Jackson ImmunoResearch) was used at
a 1:20,000 dilution. After incubation with secondary antibody,
membranes were incubated with Vistra ECF alkaline phosphatase
fluorescent substrate (Amersham, Arlington Heights, IL) and scanned
using a Storm system FluorImager (Molecular Dynamics, Sunnyvale, CA).
Immunoreactive proteins were quantified using Image Quant software
(Molecular Dynamics). To control for blot to blot variability in
background fluorescence, incubation time, and scan time, intensity of
fluorescence of FMO3 in microsomal samples was normalized to intensity
of the standard (0.7 µg of E. coli membrane fractions
containing cDNA-expressed rabbit FMO3) for each experiment. After
quantification of fluorescence, blots were rinsed and immunoreactive
proteins visualized with Western Blue alkaline phosphatase
substrate obtained from Promega (Madison, WI).
Experimental Design and Statistics.
Microsomes were prepared from livers and kidneys of at least three
separate animals or separate pools of animals for mouse experiments.
Experiments were conducted in duplicate and results are presented as
means ± S.D. of three separate experiments. Species comparisons
were made using one-way analysis of variance (
= 0.05), followed by
least-significant difference analysis, with p < .05 as
the criterion for significance. Sex comparisons were made using a
two-sample t test, with p < .05 as the
criterion for significance.
| |
Results |
|---|
|
|
|---|
Catalytic Activities of Human and Rabbit FMO3.
cDNA-expressed human FMO3 and rabbit FMO3 catalyzed the highly
diastereoselective S-oxidation of methionine, SAC, and DCVC. Reactions were monitored by measuring formation of sulfoxide
diastereoisomers using sensitive HPLC methods. Both FMO3 orthologs
catalyzed formation of the d-isomer of methionine sulfoxide
as 90 to 100% of the total sulfoxide produced (Table
1). Both FMO3 orthologs also exhibited 90 to 100% diastereoselectivity for SAC sulfoxide and DCVC sulfoxide formation. The predominant diastereoisomer formed was the later eluting
of the two sulfoxide diastereoisomers for both SAC and DCVC, however,
the absolute stereochemistry was not determined. All reactions were
protein- and NADPH-dependent and were linear for at least 75 min.
Kinetic constants were determined using double-reciprocal plots (Table
1). Kinetic constants for S-oxidation of the three substrates were nearly identical between the two FMO3 forms. Previous studies in this laboratory have also shown that rat liver FMO3 had a
Km value of 3.4 mM for methionine
S-oxidation (Krause et al., 1996
). These results suggest
that FMO3 orthologs from multiple species are catalytically very
similar with respect to SAC, DCVC, and methionine
S-oxidations.
|
Species Differences in Expression of Hepatic and Renal FMO3.
Methionine S-oxidation was used to assess FMO3 activity. The
concentration of methionine used (10 mM) was high enough to saturate FMO3, but not high enough to result in significant interference from
FMO1 or FMO2. Liver and kidney microsomes from each of the species/sexes were initially assayed for linearity of the methionine S-oxidase reaction with time and protein concentration. All
reactions were linear for at least 30 min, with the exception of male
mouse liver which was linear for 10 min, and with protein
concentrations from 0.4 to 1.4 mg/ml for liver and 0.2 to 0.6 mg/ml for
kidney (data not shown). The d-isomer of methionine
sulfoxide was formed preferentially to the l-isomer for all
species and sexes. In the liver, the formation of the
d-isomer ranged from 70 to 100% of the total methionine
sulfoxide formed, depending on the species. In the kidney, the
d-isomer ranged from 60 to 80% of the total methionine
sulfoxide formed (data not shown). The microsomal methionine S-oxidase reactions exhibited less diastereoselectivity than
the reactions with cDNA-expressed FMO3. For example, methionine
incubations with human liver microsomes produced the
d-sulfoxide as 73 to 92% of the total sulfoxide, whereas,
cDNA-expressed human FMO3 produced the d-sulfoxide as 90 to
100% of the total. One possible explanation for this is that
microsomal FMO3 displays slightly different stereoselectivity than
cDNA-expressed FMO3. This has been noted previously with cDNA-expressed
FMO1, which exhibited different stereoselectivity than purified hog
liver FMO1 (Lomri et al., 1993
). It is also possible that a small
amount of the sulfoxide produced in the microsomal reactions is due to
FMO1, FMO2, or an as yet unidentified methionine S-oxidase,
which shows less diastereoselectivity than FMO3.
|
Assessment of Sex Differences in Hepatic Microsomal FMO3 Levels Using Methionine S-Oxidase Activity and Immunoblotting. Six adult human liver microsomal samples, from three males and three females, were assayed for methionine S-oxidase activity (Fig. 1A). Although there were some interindividual differences in activity levels, there were not significant differences between males and females. Results from immunoblotting experiments agreed with those of activity assays and showed no significant differences in FMO3 expression between males and females (Fig.1, B and C).
|
|
Assessment of Sex Differences in Renal Microsomal FMO3 Levels Using Methionine S-Oxidase Activity and Immunoblotting. Methionine S-oxidase activity was determined for kidney microsomes from male and female dogs, rats, mice, and rabbits. No significant differences in activity were detected between males and females of any species (Fig. 3A). Microsomal samples were also analyzed by immunoblotting with antibody to recombinant rabbit FMO3, and the results agree with the activity assays in that no sex differences were distinguishable in any of the four species (Figs. 3B and 4B).
|
|
Relationship between Methionine S-Oxidase Activity and FMO3 Levels Detected by Immunoblotting. The levels of methionine S-oxidase activity and the levels of FMO3 determined by immunoblotting showed similar trends for all species and sexes with the exception of the mouse. The ratios of specific activity for methionine S-oxidation to relative FMO3 intensity by immunoblotting are approximately equal for dogs, rats, and humans (approximately 10:1, activity/relative intensity) (Figs. 1-3). This ratio is consistent for both males and females. Female mouse liver also exhibits an activity/intensity ratio of approximately 10:1. The ratio of activity/intensity is lower for the male and female rabbit (approximately 5:1), which is expected due to better antigenicity of rabbit FMO3 to this antibody. However, for male mouse liver and for male and female mouse kidney, there is a much higher activity/intensity ratio (approximately 100:1) than is seen in any of the other species or in the female mouse liver. In fact, immunoreactive bands were not visible in any of the three immunoblots for male mouse liver or for male or female mouse kidney (Fig. 4). Therefore, it appears that for these three tissues there is methionine S-oxidase activity that is not FMO3-mediated. The possibility that an enzyme other than FMO3 was catalyzing methionine S-oxidation was investigated in male mouse liver microsomes. Kinetic constants for methionine S-oxidation were compared between male and female mouse liver microsomes (Fig. 5). Both tissues exhibited Km values of approximately 3 mM, while the Vmax values were 2.5-fold higher for the female mouse than for the male. Stereoselectivity favoring the formation of the d-isomer of methionine sulfoxide (70-75% of total sulfoxide) was evident in both male and female mouse liver. Methionine S-oxidation in male mouse liver microsomes was inhibited by 50% by inclusion of methimazole (1 mM), but not inhibited by inclusion of benzylimidazole (1 mM), potassium cyanide (1 mM), catalase (2000 U), or superoxide dismutase (500 U) (data not shown).
|
| |
Discussion |
|---|
|
|
|---|
The purpose of the studies presented here was to investigate
whether the sex-dependence of FMO3 expression seen in mouse liver was
apparent in other commonly used laboratory species or in humans and
whether FMO3 sex-dependence was evident in the kidney. The hepatic and
renal microsomal levels of FMO3 were also compared among species. The
expression of FMO3 was assessed using an activity assay and by
immunoblotting. There have been several reports documenting the
species-, sex-, and tissue-dependence of FMO (Dannan and Guengerich, 1982
; Tynes and Hodgson, 1985
; Tynes and Philpot, 1987
; Shehin-Johnson et al., 1995
). However, all of these studies were conducted before the
time when an isoform-specific probe for FMO3 was available and most
used an antibody against purified hog liver FMO (now known as FMO1) or
antibody against purified rabbit lung FMO (now known as FMO2).
Therefore, these studies provide valuable information regarding
distribution of FMO1 and FMO2, but not FMO3. More recent studies
documenting FMO3 species-, sex-, and tissue-dependence are based on
mRNA analysis (Burnett et al., 1994
). This study is the first to look
specifically at the distribution of FMO3 at the protein level in
multiple species, sexes, and tissues.
To use an enzyme activity assay to assess FMO3 levels between species,
it was first necessary to establish that FMO3 orthologs from different
species were catalytically comparable. This was accomplished by
comparing cDNA-expressed human FMO3 with rabbit FMO3 for
S-oxidation of three different FMO3 substrates, methionine, SAC, and DCVC. Kinetic constants for the two FMO3 orthologs were nearly
identical. In addition, the previously determined
Km value for methionine
S-oxidation by purified rat liver FMO3 (3.4 mM) was very
close to that determined for human and rabbit FMO3 (3.7 and 6.4 mM,
respectively). These results suggest that FMO3 orthologs are
catalytically similar with respect to methionine and cysteine conjugate
S-oxidations, and that these reactions can be used to assess
FMO3 levels between species. Of the three substrates studied, methionine was chosen as a probe for microsomal FMO3 activity for
several reasons. FMO3 had previously been shown to be the major
methionine S-oxidase in rat and rabbit liver microsomes (Duescher et al., 1994
; Krause et al., 1996
). Both methionine and SAC
are S-oxidized at high enough rates to easily assay by HPLC,
however, SAC can also be oxidized by FMO1 with a
Km value similar to FMO3 (Ripp et al.,
1997a
). Although methionine can also be oxidized by FMO1 and FMO2, the
Km values (50 mM and 30 mM, respectively)
are much higher than for FMO3 (approximately 5 mM) (Duescher et al.,
1994
). Therefore, methionine, at a concentration of 10 mM, is a more
specific probe of FMO3 activity than SAC. DCVC is also specific for
FMO3 (Ripp et al., 1997a
), but its relatively high
Km value, low
Vmax value, and its toxicity make it less
desirable for use as a probe. It is interesting to note that the
Vmax value for DCVC oxidation is much lower
than the Vmax values for SAC and methionine
oxidations (Table 1). This suggests that the rate-limiting step for
DCVC oxidation is different from that of methionine and SAC
S-oxidations.
Methionine S-oxidase activity was used to compare microsomal
FMO3 levels among species, within the same tissue and for the same sex.
The fact that species differences in hepatic FMO3 were only noted in
males suggests that the differences may be due to varying responses to
testosterone, as noted for the mouse liver by Falls et al. (1997a)
.
Species differences in kidney microsomal FMO3 were evident in both
sexes. The rat had 2- to 6-fold higher levels than the other species.
This could be an important consideration when conducting metabolism
studies of FMO3-dependent reactions in vivo, as the rat may have
considerably more kidney metabolism than other laboratory species.
Although species differences were noted in liver and kidney microsomes,
it should be understood that these comparisons were made based on
activity normalized to microsomal protein content. Conclusions about
species differences are only valid assuming similar endoplasmic
reticulum protein backgrounds in different species.
Human liver microsomes exhibited some interindividual variability in
FMO3 levels, but on average there were no differences between males and
females. This result agrees with results from two other studies,
utilizing Western blots and activity assays, that found no sex
differences in FMO3 in human liver (Cashman et al., 1993
; Sadeque et
al., 1993
). The 2-fold interindividual variability detected in this
study is less than the variability detected in previous studies,
however, this may be explained by the small sample size and by
the relative age and race homogeneity of the human liver samples used
in this study.
When FMO3 levels were assessed in the liver and kidney of rats, mice,
rabbits, and dogs, only mouse and dog liver exhibited sex differences.
This suggests that the testosterone repression of mouse liver FMO3
noted by Falls et al. (1997a)
is species- and tissue-specific. This is
an important consideration when using the mouse for metabolism studies
that may involve FMO3. It is interesting to note that the results of
Falls et al. showed no detectable FMO3 in male mouse liver or in male
or female mouse kidney by Western or Northern blot analysis (Falls et
al., 1995
; Falls et al., 1997b
), whereas the results presented here
showed FMO3 detectable by methionine S-oxidase assay, but
not by immunoblotting. The possibility that the methionine
S-oxidase activity detected may have been due to an enzyme
other than FMO3 was investigated in male mouse liver microsomes. The
activity was inhibited by methimazole, a high-affinity FMO substrate
and competitive inhibitor, but not by the P-450 inhibitor
benzylimidazole, or the peroxidase inhibitor potassium cyanide, or by
scavengers of reactive oxygen species. This suggests that the activity
may be FMO-mediated. The Km value for
methionine S-oxidation of 2.8 mM is much closer to the
Km value for FMO3 than for FMO1 or FMO2,
which have much higher values. FMO5, which is also present in mouse
liver, has been shown to not utilize methionine as a substrate
(Duescher et al., 1994
). It is possible that some of the activity
detected in male mouse liver microsomes may be due to the presence of
FMO1 or FMO2; however, if this were the case, then contribution by FMO1
or FMO2 would also be expected in other species that are also known to
express these isoforms. This would therefore increase the
activity/intensity ratio for all species, which was not the case.
Furthermore, the stereoselectivity of methionine oxidation in male
mouse liver microsomes was similar to that observed in female mouse
liver microsomes. Therefore, it appears that there is an enzyme present
in male mouse liver microsomes and in male and female mouse kidney
microsomes that has catalytic properties, with respect to methionine
S-oxidation, similar to those of FMO3, but is not
immunoreactive with FMO3 antibody. The identity of this enzyme is
currently under investigation in this laboratory. Taken together, these
data suggest that methionine S-oxidation, using 10 mM
methionine, is a good indicator of FMO3 in liver and kidney microsomes
from humans, rats, rabbits, and dogs, but, based on the immunoblotting
results, may not be a good indicator in mice.
In summary, the results presented here show that FMO3 expression is species-, tissue-, and sex-dependent and that these factors should be considered when designing experiments that may involve FMO3-dependent metabolism.
| |
Footnotes |
|---|
Received May 5, 1998; accepted July 8, 1998.
This research was supported by Grant DK44295 (A.A.E.) from the NIDDK and by an Environmental Protection Agency graduate research fellowship (S.L.R.).
Send reprint requests to: Adnan Elfarra, School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Dr. W., Madison, WI 53706. E-mail: elfarraa{at}svm.vetmed.wisc.edu
| |
Abbreviations |
|---|
Abbreviations used are: FMO, flavin-containing monooxygenase; DCVC, S-(1,2-dichlorovinyl)-L-cysteine; HPLC, high- pressure liquid chromatography; SAC, S-allyl-L-cysteine.
| |
References |
|---|
|
|
|---|
-lyase and S-oxidase in nephrotoxicity: Studies with S-(1,2- dichlorovinyl)-L-cysteine and S-(1,2-dichlorovinyl)-L-cysteine sulfoxide.
J Pharmacol Exp Ther
269:
374-383This article has been cited by other articles:
![]() |
A. J. Lickteig, R. Riley, R. J. Melton, B. A. Reitz, H. D. Fischer, and J. C. Stevens Expression and Characterization of Functional Dog Flavin-Containing Monooxygenase 3 Drug Metab. Dispos., October 1, 2009; 37(10): 1987 - 1990. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Novick and A. A. Elfarra Purification and Characterization of Flavin-Containing Monooxygenase Isoform 3 from Rat Kidney Microsomes Drug Metab. Dispos., December 1, 2008; 36(12): 2468 - 2474. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Dever and A. A. Elfarra L-Methionine-dl-sulfoxide Metabolism and Toxicity in Freshly Isolated Mouse Hepatocytes: Gender Differences and Inhibition with Aminooxyacetic Acid Drug Metab. Dispos., November 1, 2008; 36(11): 2252 - 2260. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kammerer, H. Scheible, W. Albrecht, C. H. Gleiter, and S. Laufer Pharmacokinetics of ML3403 ({4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-Type p38 Mitogen-Activated Protein Kinase Inhibitor Drug Metab. Dispos., June 1, 2007; 35(6): 875 - 883. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. X. Hu, R. Soll, S. Yee, D. L. Lohse, A. Kousba, B. Zeng, X. Yu, A. McPherson, J. Renick, J. Cao, et al. Metabolism and Pharmacokinetics of a Novel Src Kinase Inhibitor TG100435 ([7-(2,6-Dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and Its Active N-Oxide Metabolite TG100855 ([7-(2,6-Dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine) Drug Metab. Dispos., June 1, 2007; 35(6): 929 - 936. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Elfarra and R. J. Krause S-(1,2,2-Trichlorovinyl)-L-cysteine Sulfoxide, a Reactive Metabolite of S-(1,2,2-Trichlorovinyl)-L-cysteine Formed in Rat Liver and Kidney Microsomes, Is a Potent Nephrotoxicant J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1095 - 1101. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Dever and A. A. Elfarra In Vivo Metabolism of L-Methionine in Mice: Evidence for Stereoselective Formation of Methionine-d-Sulfoxide and Quantitation of Other Major Metabolites Drug Metab. Dispos., December 1, 2006; 34(12): 2036 - 2043. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Fu, L. Xi, Y. Wu, R. McCarter, A. Richardson, M. Hickey, and E.-S. Han Hepatic Genes Altered in Expression by Food Restriction Are Not Influenced by the Low Plasma Glucose Level in Young Male GLUT4 Transgenic Mice J. Nutr., November 1, 2004; 134(11): 2965 - 2974. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Krause, L. H. Lash, and A. A. Elfarra Human Kidney Flavin-Containing Monooxygenases and Their Potential Roles in Cysteine S-Conjugate Metabolism and Nephrotoxicity J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 185 - 191. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Krause, S. C. Glocke, and A. A. Elfarra Sulfoxides as Urinary Metabolites of S-Allyl-L-Cysteine in Rats: Evidence for the Involvement of Flavin-Containing Monooxygenases Drug Metab. Dispos., October 1, 2002; 30(10): 1137 - 1142. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T. El-Alfy and D. Schlenk Effect of 17{beta}-Estradiol and Testosterone on the Expression of Flavin-Containing Monooxygenase and the Toxicity of Aldicarb to Japanese Medaka, Oryzias latipes Toxicol. Sci., August 1, 2002; 68(2): 381 - 388. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Lattard, C. Longin-Sauvageon, J. Lachuer, P. Delatour, and E. Benoit Cloning, Sequencing, and Tissue-Dependent Expression of Flavin-Containing Monooxygenase (FMO) 1 and FMO3 in the Dog Drug Metab. Dispos., February 1, 2002; 30(2): 119 - 128. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Lash and J. C. Parker Hepatic and Renal Toxicities Associated with Perchloroethylene Pharmacol. Rev., May 11, 2001; (2001) 2. [Abstract] [Full Text] |
||||
![]() |
L. H. Lash, W. Qian, D. A. Putt, S. E. Hueni, A. A. Elfarra, R. J. Krause, and J. C. Parker Renal and Hepatic Toxicity of Trichloroethylene and Its Glutathione-Derived Metabolites in Rats and Mice: Sex-, Species-, and Tissue-Dependent Differences J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 155 - 164. [Abstract] [Full Text] |
||||
![]() |
W. Jacobsen, U. Christians, and L. Z. Benet In Vitro Evaluation of the Disposition of A Novel Cysteine Protease Inhibitor Drug Metab. Dispos., November 1, 2000; 28(11): 1343 - 1351. [Abstract] [Full Text] |
||||
![]() |
B. S. Cummings and L. H. Lash Metabolism and Toxicity of Trichloroethylene and S-(1,2-Dichlorovinyl)-L-Cysteine in Freshly Isolated Human Proximal Tubular Cells Toxicol. Sci., February 1, 2000; 53(2): 458 - 466. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Lash and J. C. Parker Hepatic and Renal Toxicities Associated with Perchloroethylene Pharmacol. Rev., June 1, 2001; 53(2): 177 - 208. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||